Roche's RoActemra is better than Abbot's Humira, says Scotland, but Zelboraf fails to impress
This article was originally published in Scrip
Executive Summary
Head to head data comparing Roche's RoActemra (tocilizumab) and Abbott's Humira (adalimumab) has convinced Scotland's health technology appraisal body, the Scottish Medicines Consortium, to approve RoActemra for use on the Scottish NHS as a monotherapy for rheumatoid arthritis patients. Nevertheless, Roche is complaining about the SMC's methods for appraising end-of-life cancer drugs, after it said no to Zelboraf (vemurafenib) for metastatic melanoma patients, which Roche claims is now the standard of care in England.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.